Enzalutamide
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 3725 publications
Saruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01.
Journal: Future oncology (London, England)
Published: April 14, 2026
Proliferation associates with greater sensitivity to androgen receptor pathway inhibition for metastatic prostate cancer.
Journal: The Journal of clinical investigation
Published: March 31, 2026
Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 27, 2026
Inflation Reduction Act impact on the hematology/oncology treatment landscape.
Journal: The American journal of managed care
Published: March 26, 2026
An Optimized RNF126-Targeting Covalent Handle for Molecular Glue Degraders.
Journal: bioRxiv : the preprint server for biology
Published: March 23, 2026
Evaluating the incidence of thrombosis in patients with concurrent second-generation androgen receptor inhibitor therapy and direct oral anticoagulants: A retrospective chart review.
Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Published: March 18, 2026
Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer.
Journal: Journal for immunotherapy of cancer
Published: March 13, 2026
LC-MS/MS Method for Therapeutic Drug Monitoring of Abiraterone, Darolutamide, Apalutamide, Enzalutamide, and Metabolites in Prostate Cancer Patients.
Journal: International journal of molecular sciences
Published: March 04, 2026
Registry-based randomised phase II study of Enzalutamide versus Abiraterone: assessing cognitive function in eLderly patients with metastatic castration-resistant Prostate cancer (REAL-Pro).
Journal: ESMO real world data and digital oncology
Published: February 27, 2026
Guben Qingyuan Herbal Medicine Delays Enzalutamide Resistance in Prostate Cancer by Alleviating Tumor Hypoxia and Reprogramming Energy Metabolism in Cancer Stem Cells.
Journal: Journal of ethnopharmacology
Published: February 24, 2026
Eutectic Coamorphous System of Enzalutamide and Acetyl Maltose: A Strategy for Improved Physical Stability and Aqueous Solubility.
Journal: Molecular pharmaceutics
Published: February 23, 2026
Last Updated: 04/28/2026